PT2032134E - Métodos de tratamento da doença do fígado gorduroso - Google Patents
Métodos de tratamento da doença do fígado gorduroso Download PDFInfo
- Publication number
- PT2032134E PT2032134E PT77620334T PT07762033T PT2032134E PT 2032134 E PT2032134 E PT 2032134E PT 77620334 T PT77620334 T PT 77620334T PT 07762033 T PT07762033 T PT 07762033T PT 2032134 E PT2032134 E PT 2032134E
- Authority
- PT
- Portugal
- Prior art keywords
- inhibiting
- methods
- liver disease
- fatty liver
- treating fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74681106P | 2006-05-09 | 2006-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2032134E true PT2032134E (pt) | 2015-10-07 |
Family
ID=38621025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT77620334T PT2032134E (pt) | 2006-05-09 | 2007-05-09 | Métodos de tratamento da doença do fígado gorduroso |
Country Status (10)
Country | Link |
---|---|
US (3) | US8716327B2 (pt) |
EP (2) | EP2032134B1 (pt) |
DK (1) | DK2032134T3 (pt) |
ES (1) | ES2546181T3 (pt) |
HK (1) | HK1215533A1 (pt) |
HU (1) | HUE026057T2 (pt) |
PL (1) | PL2032134T3 (pt) |
PT (1) | PT2032134E (pt) |
SI (1) | SI2032134T1 (pt) |
WO (1) | WO2007134086A2 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1409467B1 (en) * | 2001-07-16 | 2012-04-18 | Genzyme Corporation | A n-acylsphingosine glucosyltransferase inhibitor |
JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
WO2007123200A1 (ja) * | 2006-04-21 | 2007-11-01 | Meiji Seika Kaisha, Ltd. | ペプチドを有効成分として含有する組成物 |
PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
CN101523221A (zh) * | 2006-08-08 | 2009-09-02 | 利普米克斯科技公司 | 非酒精性脂肪肝病(nafld)和非酒精性脂肪性肝炎(nash)的标记及其使用方法 |
EP2167485B1 (en) * | 2007-05-31 | 2015-09-30 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
CA2701649C (en) | 2007-10-05 | 2016-05-24 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
US20100267611A1 (en) * | 2007-10-31 | 2010-10-21 | The University Of Sydney | Treatment of metabolic disease |
EP2214709A4 (en) * | 2007-11-08 | 2011-05-11 | Univ Utah Res Found | USE OF ANGIOGENESIS ANTAGONISTS IN ABNORMAL VENOUS PROLIFERATION CONDITIONS |
US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
US20100056853A1 (en) * | 2008-08-22 | 2010-03-04 | Dymedix Corporation | Stimulus generator for a closed loop neuromodulator |
US20100069773A1 (en) * | 2008-09-12 | 2010-03-18 | Dymedix Corporation | Wireless pyro/piezo sensor system |
WO2010039256A1 (en) * | 2008-10-03 | 2010-04-08 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
HUE029371T2 (en) * | 2009-11-27 | 2017-02-28 | Genzyme Corp | GENZ 112638 For treatment of Gaucher or Fabry disease in combination therapy |
WO2011133923A1 (en) * | 2010-04-23 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Modulation of lactosylceramide synthase (lcs) expression |
WO2011133915A1 (en) * | 2010-04-23 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Modulation of glucosylceramide synthase (gcs) expression |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US20130040953A1 (en) * | 2011-08-10 | 2013-02-14 | Amy S. Paller | Promotion of wound healing |
WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
US10227323B2 (en) | 2013-09-20 | 2019-03-12 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
CA2927798C (en) | 2013-10-29 | 2022-03-15 | Biomarin Pharmaceutical Inc. | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
RU2718921C2 (ru) | 2014-10-15 | 2020-04-15 | Корсепт Терапьютикс, Инк. | Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов |
KR20180006881A (ko) | 2015-03-09 | 2018-01-19 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
WO2019082912A1 (ja) * | 2017-10-27 | 2019-05-02 | 学校法人北里研究所 | 慢性腎臓病の予防又は治療剤 |
WO2020256383A1 (en) * | 2019-06-18 | 2020-12-24 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
EP4228426A1 (en) * | 2020-12-03 | 2023-08-23 | Société des Produits Nestlé S.A. | Methods of internment caloric restriction for imparting health benefits to an animal |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309A (en) * | 1851-08-26 | Washing-machine | ||
GB1555654A (en) | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
US4065562A (en) | 1975-12-29 | 1977-12-27 | Nippon Shinyaku Co., Ltd. | Method and composition for reducing blood glucose levels |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
GB2020278B (en) | 1978-05-03 | 1983-02-23 | Nippon Shinyaku Co Ltd | Moranoline dervitives |
JPS568318A (en) | 1979-06-28 | 1981-01-28 | Janssen Pharmaceutica Nv | Non oral long acting composition of haloperidol and bromperidol derivative |
GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
EP0144290A3 (de) | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituierte Aethylendiaminderivate |
US5206347A (en) | 1985-08-06 | 1993-04-27 | La Jolla Cancer Research Foundation | Isolation and use of receptors binding to a peptide column |
US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
JPH0416856A (ja) | 1990-05-10 | 1992-01-21 | Canon Inc | 正帯電性非磁性トナー |
US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
HUT73527A (en) | 1993-08-13 | 1996-08-28 | Seikagaku Kogyo Co Ltd | Remedy for nervous diseases |
EP0742789B1 (en) | 1994-02-02 | 2000-08-30 | The Liposome Company, Inc. | Pharmaceutically active compounds and liposomes, and methods of use therof |
JP3850437B2 (ja) | 1994-06-10 | 2006-11-29 | 生化学工業株式会社 | 2−アシルアミノプロパノール化合物及び医薬組成物 |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
WO2001004108A1 (en) * | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
US6096529A (en) | 1996-06-10 | 2000-08-01 | National Research Council Of Canada | Recombinant α-2,3-sialyltransferases and their uses |
US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
US6555371B1 (en) | 1997-07-09 | 2003-04-29 | Seikagaku Kogyo Kabushiki Kaisha | Sialyltransferase and DNA encoding the same |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CA2336549A1 (en) | 1998-07-27 | 2000-02-10 | Johns Hopkins University | Methods for treating conditions modulated by lactosylceramide |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
US6255366B1 (en) | 1999-10-01 | 2001-07-03 | Eastman Chemical Company | Sulfopolymers as emulsion stabilizers with improved coagulum level |
JP5009459B2 (ja) | 1999-12-06 | 2012-08-22 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
US6407064B2 (en) | 1999-12-06 | 2002-06-18 | Seikagaku Corporation | Aminoalcohol derivative and medicament comprising the same |
US6235737B1 (en) | 2000-01-25 | 2001-05-22 | Peter Styczynski | Reduction of hair growth |
NZ522036A (en) | 2000-04-19 | 2004-04-30 | Borody Thomas J | Compositions and therapies for hyperlipidaemia-associated disorders |
US6974836B2 (en) | 2000-12-20 | 2005-12-13 | Bristol-Myers Squibb Pharma Company | Diamines as modulators of chemokine receptor activity |
CN100457719C (zh) | 2000-12-29 | 2009-02-04 | 惠氏公司 | 区域选择性制备取代的苯并[g]喹啉-3-腈和苯并[g]喹唑啉的方法 |
JP2004531478A (ja) | 2001-01-10 | 2004-10-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アミノセラミド様化合物および治療目的での使用方法 |
US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
EP1409467B1 (en) | 2001-07-16 | 2012-04-18 | Genzyme Corporation | A n-acylsphingosine glucosyltransferase inhibitor |
AU2002348261A1 (en) | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
JPWO2003057874A1 (ja) | 2001-12-28 | 2005-05-19 | 住友製薬株式会社 | 腎疾患の疾患マーカー及びその利用 |
KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 |
EP1336411A1 (en) | 2002-02-14 | 2003-08-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases |
JP2003238410A (ja) | 2002-02-21 | 2003-08-27 | Seibutsu Yuki Kagaku Kenkyusho:Kk | インスリン抵抗性解除剤 |
US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
JP4575156B2 (ja) | 2002-07-17 | 2010-11-04 | アクテリオン ファーマシューティカルズ リミテッド | グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体 |
JP4883665B2 (ja) | 2002-07-17 | 2012-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターフェロン−βを使用する腎不全のための治療法 |
WO2004078194A1 (en) * | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
US6919802B2 (en) * | 2003-07-08 | 2005-07-19 | Rf Saw Components, Inc. | Multi-layer method of accommodating code collisions from multiple surface acoustic wave identification tags |
US7423851B2 (en) | 2003-09-30 | 2008-09-09 | Tdk Corporation | Magneto-resistive element and device being provided with magneto-resistive element having magnetic nano-contact |
ATE491451T1 (de) | 2003-10-29 | 2011-01-15 | Genzyme Corp | N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz |
EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
EP1711197A4 (en) | 2003-12-23 | 2008-11-05 | Musc Found For Res Dev | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
WO2005087023A1 (en) | 2004-03-16 | 2005-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome |
EP1576894A1 (en) | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
KR20070007908A (ko) | 2004-05-07 | 2007-01-16 | 메르크 파텐트 게엠베하 | 당뇨병의 미세혈관 합병증의 치료 표적으로서의 gm3신타제 |
WO2005123055A2 (en) | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
RU2007110847A (ru) | 2004-08-20 | 2008-09-27 | Де Джонс Хопкинс Юниверсити (US) | Способы лечения ангиогенеза |
JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
EP2198864B1 (en) | 2005-01-26 | 2012-03-14 | Allergan, Inc. | Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds |
US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
WO2008011478A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008011487A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
AU2008214214B2 (en) | 2007-02-09 | 2011-09-15 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2167485B1 (en) | 2007-05-31 | 2015-09-30 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
CA2701649C (en) | 2007-10-05 | 2016-05-24 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
WO2010039256A1 (en) | 2008-10-03 | 2010-04-08 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
-
2007
- 2007-05-09 PT PT77620334T patent/PT2032134E/pt unknown
- 2007-05-09 WO PCT/US2007/068521 patent/WO2007134086A2/en active Application Filing
- 2007-05-09 HU HUE07762033A patent/HUE026057T2/en unknown
- 2007-05-09 DK DK07762033.4T patent/DK2032134T3/en active
- 2007-05-09 EP EP07762033.4A patent/EP2032134B1/en active Active
- 2007-05-09 SI SI200731687T patent/SI2032134T1/sl unknown
- 2007-05-09 US US12/227,076 patent/US8716327B2/en not_active Expired - Fee Related
- 2007-05-09 PL PL07762033T patent/PL2032134T3/pl unknown
- 2007-05-09 EP EP15162842.7A patent/EP2923699B1/en not_active Not-in-force
- 2007-05-09 ES ES07762033.4T patent/ES2546181T3/es active Active
-
2014
- 2014-04-08 US US14/247,732 patent/US9556155B2/en active Active
-
2016
- 2016-03-24 HK HK16103499.2A patent/HK1215533A1/zh unknown
- 2016-12-19 US US15/383,602 patent/US20170281593A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007134086A2 (en) | 2007-11-22 |
ES2546181T3 (es) | 2015-09-21 |
EP2032134B1 (en) | 2015-06-24 |
US9556155B2 (en) | 2017-01-31 |
US20170281593A1 (en) | 2017-10-05 |
DK2032134T3 (en) | 2015-09-28 |
EP2923699A1 (en) | 2015-09-30 |
US20150051261A1 (en) | 2015-02-19 |
SI2032134T1 (sl) | 2015-10-30 |
PL2032134T3 (pl) | 2015-11-30 |
EP2923699B1 (en) | 2018-06-20 |
WO2007134086A3 (en) | 2008-01-17 |
US8716327B2 (en) | 2014-05-06 |
US20090105125A1 (en) | 2009-04-23 |
EP2032134A2 (en) | 2009-03-11 |
HK1215533A1 (zh) | 2016-09-02 |
HUE026057T2 (en) | 2016-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2032134T3 (pl) | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów | |
EP2059588A4 (en) | FATTY ACID SYNTHESIS | |
IL197350A0 (en) | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof | |
EP1996612A4 (en) | COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2496247A4 (en) | METHOD FOR THE TREATMENT OF FATERS | |
ZA200808178B (en) | Imidazolothiazole compounds for the treatment of disease | |
SI2057136T1 (sl) | Postopki sinteze in/ali čiščenja diaminofenotiazinijevih spojin | |
IL197315A0 (en) | Treatment of cancer | |
EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
EP1991230A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
IL243294A0 (en) | Compounds and compositions for the treatment of cancer | |
EP1987838A4 (en) | NEW CONNECTION TO TUMOR THERAPY | |
FR2908771B1 (fr) | Chitine-glucane d'extrait fongique de granulometrie fine | |
HK1134295A1 (en) | Compounds and methods for synthesis and purification of oligonucleotides | |
EP2236137A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FAT TEMPERATURE DISEASES | |
EP2170351A4 (en) | METHOD AND COMPOSITION FOR TREATING CANCER AND OTHER ANGIOGENESIS-MEDIATED ILLNESSES | |
HK1129596A1 (en) | Methods and compositions for treating disease | |
EP2083831A4 (en) | PROCESSING METHOD USING FATTY ACID SYNTHESIS INHIBITORS | |
EP1986656A4 (en) | WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER | |
GB0618703D0 (en) | Synthesis of leikotriene compounds | |
GB0623740D0 (en) | Treatment of disease | |
SI2038260T1 (sl) | Stereoselektivna sinteza (S)-1-metil-3-fenilpiperazina | |
EP2099476A4 (en) | METHODS OF TREATING ALZHEIMER'S DISEASE | |
GB0600903D0 (en) | Treatment of cancer | |
GB0618309D0 (en) | Compositions and methods for the treatment of disease |